What is NewAmsterdam Pharma Company's deferred income?

NewAmsterdam Pharma Company (NAMS) reported deferred income of $3.99M in Q1 2026.

How has NewAmsterdam Pharma Company's deferred income changed year-over-year?

NewAmsterdam Pharma Company's deferred income increased by 31.6% year-over-year, from $3.03M to $3.99M.

What is the long-term trend for NewAmsterdam Pharma Company's deferred income?

Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's deferred income has grown at a -34.0% compound annual growth rate (CAGR), from $13.87M to $3.99M.

NewAmsterdam Pharma Company NAMS Deferred income

Deferred income at other companies

Lantheus HoldingsLNTH

$6.6M—

Williams CompaniesWMB

$170M+6.9%

AirbnbABNB

$2.73B+0.4%

Arthur J. GallagherAJG

$809M+28.6%

UnitedHealth GroupUNH

$3.42B+3.7%

LXP Industrial TrustLXP

$2.72M-51.6%

Other financials

Income statement

See full

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

See full

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

See full

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

See full

Market cap$3.67B+63.7%

Profitability

See full

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

See full

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NewAmsterdam Pharma Company's deferred income?: NewAmsterdam Pharma Company (NAMS) reported deferred income of $3.99M in Q1 2026.
How has NewAmsterdam Pharma Company's deferred income changed year-over-year?: NewAmsterdam Pharma Company's deferred income increased by 31.6% year-over-year, from $3.03M to $3.99M.
What is the long-term trend for NewAmsterdam Pharma Company's deferred income?: Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's deferred income has grown at a -34.0% compound annual growth rate (CAGR), from $13.87M to $3.99M.